Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 4/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | TYK2 | P29597 | 3/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28329731 | 0.91 | ALOX5AP (0.40) | GRM4PIK3CALRRK2FFAR2ATXN2 | |
| SCHEMBL20689409 | 0.84 | TYK2 (0.47) | GRM4MAPK8MAPK9AKT1PIK3CA | |
| SCHEMBL20689128 | 0.84 | TYK2 (0.47) | GRM4MAPK8MAPK9AKT1PIK3CA | |
| SCHEMBL2839113 | 0.83 | LRRK2 (0.44) | GRM4MAPK8MAPK9AKT1PIK3CA | |
| SCHEMBL24723259 | 0.80 | AKT1 (0.39) | MAPK8MAPK9AKT1PIK3CAMTOR | |
| SCHEMBL20396370 | 0.79 | LRRK2 (0.36) | GRM4MAPK8MAPK9AKT1PIK3CA | |
| SCHEMBL17594827 | 0.76 | IRAK4 (0.38) | PIK3CALRRK2ATXN2ALOX5APFEN1 | |
| SCHEMBL19171720 | 0.75 | MAPK1 (0.41) | GRM4PIK3CALRRK2TYK2ATXN2 | |
| SCHEMBL16667921 | 0.74 | PIK3CA (0.44) | GRM4MAPK8MAPK9AKT1PIK3CA | |
| SCHEMBL16667919 | 0.74 | PIK3CA (0.44) | GRM4MAPK8MAPK9AKT1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352300-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190352300-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| US-10316038-B2 | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer | ACLARIS THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316038-B2 | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer | ACLARIS THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| WO-2018140648-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | JACOBSEN ERIC JON (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140648-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | JACOBSEN ERIC JON (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20180208594-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2018-07-26 | — | — | US | disclosed |
| US-20180208594-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2018-07-26 | — | — | US | disclosed |
| US-20180208594-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316038-B2 | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer | ITK, PDXK, WEE1 | GRM4 3688/4885MAPK8 651/4885MAPK9 626/4885 |
| US-20190352300-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, PDXK, WEE1 | GRM4 3688/4885MAPK8 651/4885MAPK9 626/4885 |
| US-20180208594-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, PDXK, WEE1 | GRM4 3688/4885MAPK8 651/4885MAPK9 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.